OC 52.3 Efficacy and Safety of Fidanacogene Elaparvovec in Adults with Moderately Severe or Severe Hemophilia B: Results from the Phase 3 BENEGENE-2 Gene Therapy Trial

Autor:	Cuker, A., Alzahrani, H., Astermark, J., Frenzel, L., Katsarou, O., Kavakli, K., Klamroth, R., Matino, D., Shapiro, A., Wang, J., Fuiman, J., McKay, J., Sun, P., Rupon, J.
Zdroj:	In Research and Practice in Thrombosis and Haemostasis October 2023 7 Supplement 2
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Plný text